ClinicalTrials.gg
CompletedNCT07071779WAIT-AYAUpdated Nov 12, 2026

Web-based Alcohol- or Cocaine-specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder

An interventional study of Substance-specific inhibition training and Control training in Alcohol Use Disorder (AUD), Cocaine Use Disorder (CUD) and Substance Use Disorder (SUD), sponsored by University of Bern. Completed at 1 site in Switzerland. Open to participants aged 14 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Bern · Not applicable, Interventional, and Other

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
14 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Alcoholism with a site in Switzerland — 4 open to participants now, 4 under way, none of them phase 3. Alcoholism · Switzerland.

Enrollment
10th of 10
15 · median 57
Started
2025
with 2 others
No phase
5 of 12
2 open now
Registered
12th of 12
by date
Lead sponsor
5 of 12
University of Bern

Among the 12 studies in Alcoholism with a site in Switzerland, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 12th registered.

Alcoholism

1,678 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

4 of the 12 studies in Alcoholism with a site in Switzerland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 14 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Alcoholism with a site in Switzerland, or all of them as a file.
02

Study summary

Substance misuse is one of the most common risk factors for health problems and premature death among adolescents and young adults worldwide. Although there are effective treatments for substance use disorder (SUD), there is still a need to further improve their effectiveness and make them easier to access. Early research suggests that substance-specific inhibition training, when used in addition to specialized treatment, can improve treatment outcomes. This training aims to strengthen inhibition specifically in situations with substance-related cues. The goal of this project is to offer this training for the first time in the form of a smartphone app, which is expected to increase the availability of the training. The main aim of the study is to evaluate whether this new app-based cognitive training is feasible as an add-on to the treatment of SUD in adolescents and young adults. In addition, the study will gather preliminary insights into whether the training affects drinking behavior and related brain processes. The project will be conducted as a double-blind, clinical pilot study. A total of 210 adolescents and young adults between 14 and 35 years old will be recruited from five specialized treatment centers. After the first study visit, participants will be randomly assigned to one of two groups: (1) an intervention group receiving the alcohol-specific inhibition training or (2) a control group receiving a similar alcohol-nonspecific inhibition training. During their participation, all participants will complete six short training sessions with the app. About one month later, they will complete six additional booster training sessions. This research may help develop effective, easily accessible tools to support young people with substance use disorder.

03

Conditions studied

  • Alcohol Use Disorder (AUD)
  • Cocaine Use Disorder (CUD)
  • Substance Use Disorder (SUD)

Keywords

  • Alcohol use disorder
  • Alcohol-specific inhibition training
  • Cognitive bias modification
  • Feasibility pilot randomized controlled trial
  • Cocaine Use Disorder (CUD)
  • Substance Use Disorder (SUD)
  • Cocaine-specific inhibition training
  • Substance-specific inhibition training
04

Who can participate

Ages eligible
14 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 14 - 35 years
  • Alcohol use disorder identification test (AUDIT) ≥ 7 or Drug Use Identification Test (DUDIT) ≥ 8
  • Currently undergoing outpatient treatment or online counselling in one of 7 specialized treatment settings
  • Sufficient German language skills
  • as documented by signature
  • Owner of a smartphone with internet access

Exclusion criteria

Exclusion Criteria:

  • Other severe substance use (except nicotine and cannabis) determined by the cut-off value ≥ 25 in the drug use disorder identification test (DUDIT)
  • Current medical conditions excluding participation
  • Inability to read and understand the participant's information
  • Enrolment of the investigator, his/her family members, employees, and other dependent persons

Additional exclusion criteria for Electroencephalography (EEG)-substudy:

  • Current medication affecting EEG (e.g., benzodiazepines)
  • Other severe substance use determined by the cut-off value ≥ 25 in the DUDIT (except nicotine)
  • History of epilepsy
  • Cochlea implant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Substance-specific inhibition training

    12 sessions of substance-specific inhibition training

    Other: Substance-specific inhibition training

  • Active comparator
    Control training

    12 sessions of unspecific inhibition training

    Other: Control training

Interventions

  • OtherSubstance-specific inhibition training

    Twelve sessions of substance-specific inhibition training

  • OtherControl training

    Twelve sessions of unspecific inhibition training

06

What researchers measure

Primary outcomes

  1. Number of participants recruited

    Number of participants recruited during the recruitment period in all participating clinical centers is one indicator of the feasibility of implementing substance-specific inhibition training in a smartphone app.

    Time frame: From enrollment to the last assessment, approx. 16 weeks

  2. Number of participants successfully completing the program

    Number of participants successfully completing the program is one indicator of the feasibility of implementing substance-specific inhibition training in a smartphone app.

    Time frame: At the last assessment, approx. 16 weeks from enrollment

  3. Proportion of participants completing the follow-up visits

    Proportion of participants completing the follow-up visits is another indicator of feasibility.

    Time frame: At the last assessment, approx. 16 weeks from enrolment

  4. Number of participants adhering to the treatment

    Number of participants adhering to the treatment, i.e. participating in all planned twelve training sessions, is another indicator of feasibility of implementing substance-specific inhibition training in a smartphone app.

    Time frame: From enrollment to last last training session, approx. 10 weeks

  5. Number of adverse events

    Number of adverse events is another indicator of feasibility of implementing substance-specific inhibition training in a smartphone app.

    Time frame: From enrollment to the last assessment, approx. 16 weeks

Secondary outcomes

  1. Percentage of days abstinent

    Percentage of days abstinent is the main secondary outcome indicating preliminary effects on consumption behavior. It is measured by the Timeline Follow-Back method at 3-month follow-up.

    Time frame: At the last assessment, approx. 16 weeks from enrolment

  2. Number of heavy drinking days

    Number of heavy drinking days is another secondary outcome indicating preliminary effects on drinking behavior. It is measured by the Timeline Follow-Back method at 3-month follow-up.

    Time frame: At the last assessment, approx. 16 weeks from enrolment

  3. P3-component of event-related potentials

    The P3-component of event-related potentials measured with electroencephalography (EEG) is used as a secondary outcome in the EEG- substudy to investigate whether substance-specific inhibition training modifies the neurophysiology of substance-specific inhibition

    Time frame: 4-6 weeks.

  4. N2-component of event-related potentials

    The N2-component of event-related potentials measured with electroencephalography (EEG) is used as a secondary outcome in the EEG- substudy to investigate whether substance-specific inhibition training modifies the neurophysiology of substance-specific inhibition

    Time frame: 4-6 weeks.

07

Study locations

1 site
08

References and documents

Publications

  • Schuerch K, Koenig T, Guarriello A, Soravia L, Berger T, Adorjan K, Moggi F, Stein M. Mobile alcohol-specific inhibition training in adolescents and young adults with alcohol use disorder: study protocol for a randomized controlled feasibility trial. Front Psychol. 2026 Apr 22;17:1684231. doi: 10.3389/fpsyg.2026.1684231. eCollection 2026. PubMed 42099725 ↗

Individual participant data

Plan to share: No — The decision to share IPD depends on the explicit consent provided by participants as part of the informed consent process. Since it is not possible to determine in advance whether participants will grant permission for data sharing, IPD sharing is not planned.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Oct 2026, 14 months.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's 14 months is below that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Jul 17, 2025
StartActual
Jul 23, 2025
Primary completionActual
Oct 12, 2026was Aug 2026
CompletionActual
Oct 12, 2026was Aug 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 12, 2026
Primary completion
Aug 2026→Oct 12, 2026 (actual)
Nov 12, 2026
Study completion
Aug 2026→Oct 12, 2026 (actual)
Nov 12, 2026
Enrollment
210 (estimated)→15 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Completed
    Primary completion Aug 2026→Oct 12, 2026 (now actual)
    Study completion Aug 2026→Oct 12, 2026 (now actual)
    Enrollment 210 (estimated)→15 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07071779
Lead sponsor
University of Bern
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
Jul 23, 2025
Primary completion
Oct 12, 2026
Completion
Oct 12, 2026
Last update
Nov 12, 2026

Study contacts

Maria Stein, PD Dr.
principal investigator · University of Bern

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion